● COVID-19

  • ʻO ka maʻi maʻi maʻi SARS-CoV-2 A influenza B Hui Pū ʻIa Nucleic

    ʻO ka maʻi maʻi maʻi SARS-CoV-2 A influenza B Hui Pū ʻIa Nucleic

    He kūpono kēia kit no ka ʻike in vitro qualitative o SARS-CoV-2, influenza A a me ka influenza B nucleic acid o ka nasopharyngeal swab a me nā oropharyngeal swab samples o ka poʻe i manaʻo ʻia i ka maʻi o SARS-CoV-2, influenza A a me ka influenza. B.

  • Nā ʻano like ʻole SARS-CoV-2

    Nā ʻano like ʻole SARS-CoV-2

    Hoʻolālā ʻia kēia pahu i ka ʻike in vitro qualitative o ka coronavirus novel (SARS-CoV-2) i nā laʻana o nā nasopharyngeal a me nā oropharyngeal swab samples.ʻIke ʻia ka RNA mai SARS-CoV-2 i nā ʻano hanu i ka wā o ka maʻi o ka maʻi a i ʻole ka poʻe asymptomatic.Hiki ke hoʻohana hou ʻia ka ʻike qualitative a me ka ʻokoʻa o Alpha, Beta, Gamma, Delta a me Omicron.

  • ʻO ka pahu RT-PCR fluorescent manawa maoli no ka ʻike ʻana iā SARS-CoV-2

    ʻO ka pahu RT-PCR fluorescent manawa maoli no ka ʻike ʻana iā SARS-CoV-2

    Ua manaʻo ʻia kēia kit e ʻike pono i nā genes ORF1ab a me N o ka novel coronavirus (SARS-CoV-2) i loko o ka nasopharyngeal swab a me ka oropharyngeal swab i hōʻiliʻili ʻia mai nā hihia a me nā maʻi puʻupuʻu i manaʻo ʻia me ka novel coronavirus-infected pneumonia a me nā mea ʻē aʻe i koi ʻia no ka maʻi. a i ʻole ka maʻi ʻokoʻa o ka maʻi coronavirus hou.